Importance: 104
Introduction 48
The seven members of the APOBEC3 (A3) gene family in primates encode 49 cytidine deaminases involved in innate immune defense against retroviruses and 50 retroelements (1-3). Four A3 enzymes are known to potently restrict the replication of 51 lentiviruses like simian immunodeficiency virus (SIV) or human immunodeficiency virus 52 (HIV): A3D, A3F, A3G, and A3H (4). A3 proteins are packaged into budding virions and 53 cause G-to-A hypermutation of viral DNA, although deamination-independent modes of 54 restriction have also been characterized (5). Hypermutation of viral DNA results in 55 detrimental mutations that render the virus inactive and thus protects new cells from 56 infection. However, lentiviruses have evolved a mechanism to evade A3 restriction by 57 encoding a viral antagonist, Vif, which binds and targets A3 proteins for proteasomal 58 degradation via a cellular E3 ubiquitin ligase complex (6) . Given that A3-Vif interactions 59 often act in a species-specific manner, adaptation of Vif to host A3 proteins is important 60 for successful adaptation of lentiviruses to their hosts (7) (8) (9) (10) (11) . 61
Various A3 proteins differ in their ability to restrict viral infection. For instance, 62 A3G is the most potent A3-mediated inhibitor of HIV-1, while A3A and A3B have limited 63 antiviral potential (4, 12) . In humans, the A3H protein is especially remarkable because 64 multiple polymorphisms drastically impact its antiviral activity (13) (14) (15) (16) . Two independent 65 mutations have occurred in human evolution that destabilized A3H (13); haplotypes that 66 encode an R105G mutation or a deletion of amino acid 15 make unstable proteins 67 (haplotypes I, III, IV, VI) that have lost antiviral activity, while those without these 68 changes make stable proteins (haplotypes II, V, VII) that potently restrict 69 17) . Stability and antiviral activity of human A3H has been further linked to subcellular 70 localization: unstable/inactive proteins are more nuclear, while stable/active proteins 71 remain cytoplasmic (18). A3H haplotype I has been associated with breast and lung 72 cancer (19), as has another nuclear A3, A3B (20) , suggesting that in some cases A3 73 activity may be detrimental for the host. While such events have occurred in humans, 74 examples of gains or losses of A3 activity over evolutionary time in other primates have 75 been less explored. 76
The A3H genetic polymorphisms present in human populations also impact the 77 interactions between human A3H and HIV-1 Vif (17, (21) (22) (23) . Stable A3H proteins are 78 only partially susceptible to degradation by Vif from the LAI isolate of HIV-1 and not at 79 all by HIV-1 NL4-3 Vif (21, 23) . However, studies using human cohorts encoding 80 different haplotypes of A3H have shown that Vif proteins from primary virus strains 81 isolated from patients with A3H haplotype II are able to antagonize stable proteins, 82 while those from patients with unstable haplotypes cannot. This suggests that there is 83 selection in vivo for Vif strains that counteract the stably expressed forms of A3H in 84 infected people (22, 24, 25) . Furthermore, the cross-species transmissions that led to 85 adaptation of SIV from monkeys to chimpanzees to humans, giving rise to 86 involved adaptation of Vif to antagonize the A3 proteins found in each host (7, 8, 10, 11) 87 including adaptation of Vif from SIVcpz to antagonize human A3H (11) . 88
The study of the evolution of lentiviral-host interactions within Old World monkeys 89 has provided insights into the longer-term dynamics of the evolutionary arms race 90 between host antiviral proteins and their lentiviral targets (7, 9, 26) . African green 91 monkeys (AGMs), in particular, provide a unique opportunity to assess the evolutionary 92 forces governing interactions between lentiviruses and their hosts since the genus 93
Chlorocebus encompasses four geographically distinct subspecies (vervets, sabaeus, 94 tantalus, and grivets) each of which are infected with species-specific subtypes of 95
SIVagm (27) (28) (29) . These SIV subtypes are named by the subspecies they infect: 96
SIVagm.ver, SIVagm.sab, SIVagm.tan, and SIVagm.gri (29) . Furthermore, this system 97 is particularly powerful because although these subspecies are closely genetically 98 related, enough divergence exists that has allowed species-specific lentiviral infections 99 to occur. 100
Previous studies have demonstrated that many genes involved in antiviral 101 immunity are polymorphic in AGMs and some changes at the protein level are critical for 102 interactions with viral antagonists (8, 30, 31) . A3G in particular was discovered to 103 encode species-specific polymorphisms (8). Amino acid changes in the Vif binding 104 domain of AGM A3G (sites 128 and 130) confer protection against SIVagm strains from 105 other subspecies. For example, K128E, found in grivet monkeys, is resistant to all Vifs 106 except SIVagm.gri, while D130H, found in sabaeus monkeys, is resistant to Vifs from 107
SIVagm.ver and SIVagm.tan (8). This demonstrates that Vif continues to drive the 108 evolution of A3G and contributes to the species-specificity of lentiviruses in AGM 109 populations. It is unknown whether A3H has a similar role in these primates. 110
In this study, we asked whether we could identify a host-virus "arms-race" 111 between A3H in AGMs and Vif proteins encoded by the SIVs that infect these species. 112
Surprisingly, we found that although A3H is highly polymorphic in AGMs, the antiviral 113 activity of A3H has been largely lost in AGMs. The reduced antiviral activity of AGM 114 A3H is in part caused by lower protein expression levels, although amino acid changes 115 also lower antiviral activity independent of protein levels. By reconstructing ancestral 116 A3H proteins spanning evolution in AGMs and in other Old World monkeys, we find that 117 there has been recurrent loss of A3H activity in some, but not all, Old World monkeys. 118
While higher expression levels generally increase viral inhibition, we also identified 119 amino acids that affect A3H restriction without increasing protein expression, which map 120 to regions implicated in RNA binding (32) (33) (34) . Thus, our data support a model where 121
A3H antiviral activity has been repeatedly lost throughout evolution. This argues that 122 there is a longer scale dynamic between the cost and benefit for A3H function in 123 primates that is not necessarily driven by interactions with its antagonist. 124
125

Results
126
A3H is highly polymorphic in AGM subspecies, but all tested alleles have low 127 antiviral activity. 128
Polymorphisms in human A3H are known to affect its antiviral activity as well as 129 its interactions with Vif (13, 15, 17, 22, 23) . Similarly, polymorphisms in A3G in AGMs 130 impact interactions with Vif, suggesting an ongoing and ancient genetic conflict between 131 A3G and SIV Vif in AGMs (8). These observations prompted us to explore the genetic 132 landscape of A3H in African green monkeys and other Old World monkeys to determine 133 if A3H evolution has been driven by Vif over a broad evolutionary scale. First, we 134 sequenced A3H in 50 AGM samples collected from all four subspecies infected with a 135 species-specific SIV: vervet, sabaeus, tantalus, and grivet monkeys. The mitochondrial 136 DNA of these animals had also been previously sequenced and was confirmed to 137 cluster by AGM subspecies (8). Sequence analysis of 80 independent A3H genes 138 revealed 34 single-nucleotide polymorphisms (SNPs), 6 of which are synonymous 139 changes at a frequency higher than 5%. 28 SNPs are nonsynonymous; 23 are found in 140 more than one individual (Table 1) . Most polymorphisms are represented in all four 141 subspecies ( Figure 1A and B), except for low frequency variants only found in one AGM 142 and two nonsynonymous mutations found in two vervet sequences at amino acid 143 residues 113 and 116. Phylogenetic analysis showed that A3H sequences from all AGM 144 subspecies are paraphyletic ( Figure 1A ), similar to a previous study examining A3G in 145 these species (8) . 146
Nonsynonymous SNPs are spread throughout the protein (Table 1) , although 147 one group is clustered between amino acids 127 -139. The changes are tightly linked 148 and result in divergence of the phylogenetic tree between two clades ( Figure 1A , red 149 arrow). Haplotypes with a CGRELP motif compose one clade on the tree, while the 150 other has an SRQKRQ motif. Residues 127 and 128 are located on the 4 helix, which 151 has been implicated in A3H-Vif binding (35, 36) . Furthermore, the regions of A3H with 152 the greatest number of nonsynonymous mutations are in the predicted loops 1 and 7, 153 and the 6 helix (Table 1) , which were recently shown by structural studies to be 154 involved in an interaction between A3H and a co-crystalized RNA (32-34). These results 155 indicate that, similar to A3G, SAMHD1, and other antiviral genes in AGMs (7, 30, 31) , 156 there is extensive polymorphism in AGM A3H. 157
The presence of numerous polymorphisms suggests there may be functional 158 consequences for either antiviral activity or Vif antagonism. To determine whether or not 159 nonsynonymous polymorphisms in A3H impact antiviral activity, we tested the ability of 160 A3H protein variants to restrict lentiviruses. We cloned haplotypes, numbered 1 -11, 161 which are representative of each clade in the phylogenetic tree into a mammalian 162 expression vector for functional analysis ( Figure 1B ). These haplotypes also represent 163 all four subspecies of AGMs. Out of the 28 total nonsynonymous SNPs found in AGMs 164 (Table 1) , 11 unique protein sequences were tested and 20 polymorphic sites were 165 characterized ( Table 2) . 166 A3H expressing plasmids were co-transfected into HEK293T cells for single-167
round infectivity experiments with HIVenvvif or SIVagm.TANenvvif proviruses and 168 a VSV-G expression plasmid for pseudotyping to measure antiviral activity. Viral 169 supernatants were collected, normalized for RT activity, and used to infect SupT1 cells. 170
We found that none of the AGM A3H variants restricted lentiviruses as potently as the 171 A3H from rhesus macaque (Figure 2A) , an Old World monkey that has been previously 172 characterized for its A3H activity (4, 13, 14) . Rhesus A3H restricted viral infection of 173
HIVvif by approximately 21-fold, while AGM A3H variants restrict viral infection by no 174 more than 3-fold, and some not at all ( Figure 2A ). Although activity against HIV-1vif 175 correlates with activity against other lentiviruses, we also validated this result using 176
SIVagm.TANvif, a strain originally isolated from tantalus monkeys. We found that the 177 AGM A3H haplotypes were also poorly restrictive against SIVagm.TANvif compared to 178 the activity of rhesus macaque A3H (Figure 2A ). This indicates A3H variants encoded 179 by AGMs have poor antiviral activity against at least two separate lentiviruses and is not 180 due to species-specificity ( Figure 2B ). 181
The differences in restriction could be explained by changes in expression since 182 we found that no variant of AGM A3H is as strongly expressed as rhesus macaque A3H 183 in HEK293T cells ( Figure 2B , top). This lower expression of AGM A3H proteins relative 184 to rhesus macaque A3H was not due to the species of origin of the cells used for 185 transfection since when we transfected AGM-derived Cos7 cells, the protein expression 186 levels of AGM A3H were similarly poor relative to the expression of the rhesus A3H 187 ( Figure 2B , bottom). These data indicate that lower protein expression levels are 188 correlated with less potent antiviral activity, similar to unstable haplotypes of human 189
A3H. 190
To ask whether lower antiviral activity of AGM A3H proteins was due to low 191 expression levels alone, we selected one of the most potent AGM A3H proteins, 192 haplotype 1 (Figure 2A) , and increased the amount of transfected plasmid from 200ng 193 to 1000ng in parallel to rhesus macaque A3H. At the highest plasmid concentration, 194 haplotype 1 was able to restrict HIVvif 16-fold, while rhesus A3H restricted fold at the lowest concentration used ( Figure 2C as the protein concentration increases, the antiviral activity correspondingly becomes 201 more potent. 202
In order to more fully explore the relationship between expression levels and 203 antiviral activity of AGM A3H, we codon-optimized both AGM A3H haplotype 1 and 204 rhesus macaque A3H sequences to remove rare codons that might negatively affect 205 protein translation efficiency. Based on codon-usage statistics in primates (see 206
Methods) 100 out of 211 codons were replaced to more frequent codons in the codon-207 optimized AGM haplotype 1 A3H and 106 out of 211 were replaced in the codon-208 optimized rhesus macaque A3H. We found that codon-optimization of both AGM A3H 209 and of rhesus macaque A3H increased their expression levels relative to the native 210 codons in each gene ( Figure 3A -compare WT to CO (codon-optimized)). Moreover, 211 after codon-optimization, AGM A3H haplotype 1 and rhesus macaque A3H are 212 expressed to similar levels ( Figure 3A and Figure 3B , bottom). However, while codon 213 optimization increased the antiviral activity of both AGM and rhesus macaque A3H over 214 that of wild-type (compare Figure 3B to 2D), codon-optimized rhesus macaque A3H still 215
This shows that while increasing the expression level of the protein is sufficient to 217 improve its antiviral activity, other factors also influence protein function. 218
Studies in humans have shown that inactive A3H proteins also localize to the 219 nucleus (13, 18). We therefore asked whether AGM A3H proteins were expressed to 220 lower levels with low antiviral activity due to a change in localization. WT AGM A3H 221 haplotype 1 and WT rhesus macaque A3H were transfected into HeLa cells and 222 visualized using immunofluorescent microscopy. However, both AGM and rhesus 223 macaque A3H were mainly present in the cytoplasm ( Figure 3C ), demonstrating that a 224 drastic change in localization was not responsible for the lack of potent antiviral activity 225 of AGM A3H. 226
Our results suggest that the extensive diversity observed in AGM A3H results in 227 lower antiviral activity linked to both protein levels and to other functional differences 228 due to amino acid divergence between species. 229 230
Reconstruction of ancestral A3H proteins demonstrates the loss of activity in 231 more recent evolution of AGMs and other primates 232
We previously explored the evolutionary dynamic of hominoid A3H by 233 reconstructing the ancestor of human/chimpanzee A3H and found that the predicted 234 A3H protein at the human/chimpanzee ancestor had higher antiviral activity than either 235 the extant chimpanzee or human proteins (13). This suggests that there has been a loss 236 of some activity in both lineages over their evolution. Due to the finding that all tested 237 AGM A3H proteins are poorly active relative to the rhesus macaque A3H, we wanted to 238 reconstruct the ancestral history of A3H leading to the modern AGM lineage. Thus, in 239 order to gain statistical power in the ancestral sequence predictions at each node, we 240 determined the A3H sequence from a broader panel of Old World monkeys in sister 241 clades including De Brazza's monkey, Allen's Swamp monkey, Wolf's guenon, 242 mustached guenon, talapoin, and patas monkey ( Figure 4A ). 243
We tested the A3H activity of the closest sister species to the AGMs, patas 244 monkeys, and the A3H activity of a sister species to the rhesus, the sooty mangabey 245 ( Figure 4A ). Upon transfection into HEK293T cells, the protein expression level of patas 246 monkey A3H was lower in comparison to rhesus macaque A3H, similar to AGM A3H 247 ( Figure 4B , bottom). Patas monkey A3H correspondingly had low antiviral activity when 248 tested against HIVvif; that is, while AGM and rhesus macaque A3H restricted viral 249 infection 6-fold and 63-fold, respectively, patas monkey A3H restricted HIVvif infection 250 only 3-fold ( Figure 4B , top). However, active A3H proteins from sooty mangabey and 251 the human A3H haplotype II restrict viral infection 20-fold and 40-fold, respectively. 252
These data show that the antiviral activity is low in a species closely related to AGMs, 253 but a relative of the rhesus macaque and humans encode more active A3H proteins. 254
This finding further suggests that changes in A3H activity may have deeper evolutionary 255 origins in primate evolution. 256
In order to determine whether A3H antiviral activity was gained in the rhesus 257 macaque/sooty mangabey lineage, or was lost in the AGM/patas monkey lineage, we 258 reconstructed the A3H ancestors at various nodes in the Old World monkey phylogeny 259 ( Figure 4A ). These included the common ancestor of AGMs and patas monkeys (node 260 1), AGMs, patas monkeys, and its sister clade (node 2), as well as the common 261 ancestor of rhesus macaque, pig-tailed macaque, and sooty mangabey (node 3) and 262 common ancestor of both groups (node 4). Each ancestor was constructed using 263 maximum likelihood with FastML (37) based on the primate species phylogeny. 264
Although the majority of codons were reconstructed with a probability >99%, site 207 265 was ambiguous in the common ancestor of all tested Old World monkeys and two 266 codons were possibleencoding either an isoleucine (node 4a) or a threonine (node 267 4b) at position 207. In this case, both possible ancestors were generated using point-268
mutagenesis. 269
We then tested the predicted A3H protein at the reconstructed ancestral nodes of 270 the Old World monkey phylogenetic tree for antiviral activity and protein expression 271 level. All ancestors inhibited viral infection between 17-and 33-fold ( Figure 4C ). Thus, 272 this result suggests that activity was lost within the AGM/patas monkey clade rather 273 than specifically gained in the rhesus macaque/sooty mangabey clade. Moreover, the 274 node 1 ancestor representing the common ancestor of AGM and patas monkeys 275 restricted viral infection 33-fold, which was more potent than its descendants, AGMs (6-276 fold) and patas monkeys (3-fold), despite having similar protein expression levels 277 ( Figure 4C ). Therefore, loss of activity in A3H in AGM and patas monkeys that occurred 278 after the common ancestor at node 1, which diverged at least 4 million years ago (27), 279 included mutations that both decreased protein expression levels and led to the losses 280 of antiviral activity that are independent of protein expression. 281
282
Multiple amino acid mutations are responsible for loss of A3H antiviral activity. 283
The ancestral A3H protein at node 1 representing the common ancestor of AGMs 284 and patas monkeys ( Figure 4A ) has stronger antiviral activity than its extant 285 descendants ( Figure 4C ). Therefore, we wanted to trace the amino acid mutations that 286 resulted in the subsequent loss along the branches leading from node 1 to AGMs and 287 patas monkeys. The sequence alignment of the node 1 ancestor with AGM haplotype 1 288 and patas monkey A3H reveals 4 (sites 18, 20, 48, and 171) and 3 (sites 17, 25, and 289 51) amino acid differences respectively ( Figure 5A ). One site in AGMs, S20N, created a 290 protein sequence identical to AGM A3H haplotype 8. We introduced the other residues 291 found in the node 1 ancestor into AGM and patas monkey A3H backgrounds to test the 292 expression level and antiviral activity of each mutant. 293
Notably, no single amino acid mutation in AGM A3H increased the antiviral 294 activity compared to wild-type AGM A3H and all single mutants inhibited viral infection 295
around 5-fold relative to the no A3 control ( Figure 5B ). In contrast, the double mutants 296 H18R/S20N, H18R/Q48K, and S20N/Q48K, antiviral activity increased to around 13-fold 297 which is still less than the node 1 ancestor (17-fold; Figure 5B ). Similarly, patas monkey 298 A3H with single mutations at sites 25 (R25P) and 51 (E51K) did not improve restriction, 299 while a H17R mutation slightly increased the antiviral activity compared to wild-type (3-300 fold to 5-fold; Figure 5B ). However, this single mutation at position 17 did not make 301 patas monkey A3H comparable to the node 1 ancestor. Inserting both H17R and R25P 302 mutations in patas monkey A3H similarly did not further improve restriction ( Figure 5B) . 303
Taken together, the inability of single point mutations to restore antiviral activity to its 304 ancestral state emphasizes that changes at multiple sites have functional 305 consequences in AGM and patas monkey A3H. 306
Of interest, site 48 is the only residue that is fixed in all AGMs sequenced for this 307 study. This demonstrates that it occurred first, whereas the other sites are polymorphic 308 and have not yet become fixed in the species (Table 1) . To determine whether site 48 309 alone is sufficient to decrease antiviral activity we added a K48Q mutation in the node 1 310 background and tested its antiviral activity. However, node 1 K48Q has similar antiviral 311 activity and expression ( Figure 5C, bottom) , showing that epistasis between multiple 312 amino acids may play an essential role for viral restriction by A3H. 313
Overall, these data establish that amino acids in the N-terminal portion of A3H 314 are important for antiviral activity. While no tested combinations increase the antiviral 315 activity of AGM or patas monkey A3H equivalent to the node 1 ancestor, all changes 316 (minus one) are before the catalytic domain ( Figure 5A ). Two out of 3 residues 317 responsible for the loss of activity in patas monkey A3H, sites 17 and 25, are also 318 polymorphic in AGMs (Table 1 ), suggesting that the loss began at a shared common 319 ancestor not sampled by our analysis. Significantly, many Old World monkeys encode 320 additional mutations near amino acid 15, whose loss in human A3H is known to affect 321 protein stability (13). For example, residues 18 -23 have been deleted in De Brazza's 322 monkey ( Figure 5A ). Such a large deletion in this region would likely impact the ability of 323 A3H to inhibit viral infection in this species. Similarly, talapoin A3H encodes a histidine 324 at position 18 instead of an arginine, similar to AGM A3H, suggesting that its activity 325 may also be lost ( Figure 5A ). In contrast, rhesus macaque and sooty mangabey A3H 326 encode active ancestral amino acids at such residues, such as two arginines at 327 positions 17 and 18 ( Figure 5A ), which may result in the potent antiviral activity of these 328 modern proteins. This implies that loss of A3H function has been lost independently at 329 various points of evolutionary history in both hominoids and Old World monkeys. 330 331 Lack of evidence that evolution in A3H leading to AGM has been driven by Vif. 332
The variability in A3H function throughout Old World monkey evolution suggests 333 an outside selective pressure is driving its loss. Antiviral restriction factors are often 334 rapidly evolving and undergo positive selection (38), which is defined by an excess of 335 nonsynonymous mutations compared to synonymous mutations. Evolutionary conflicts 336 between host restriction factors and viral proteins to either maintain or escape 337 interactions result in an accumulation of nonsynonymous mutations at binding 338 interfaces. A previous study found that A3H is under positive selection (14). However, 339
the study used fewer primate sequences which can bias the analysis. Therefore, we 340
wanted to re-test positive selection in primate A3H using additional sequences we 341 obtained from Old World monkeys. Using the PAML (phylogenetic analysis by maximum 342 likelihood) program (39), we calculated the number of nonsynonymous mutations (dN) 343 over the number of synonymous mutations (dS) for the entire A3H gene as well as 344 individual codons. In agreement with previous data, we found that the A3H gene is 345 under positive selection and with a dN/dS ratio of 1.3 in all primates. Additionally, 346 models that allow codons to evolve under positive selection fit the data significantly 347 better than models that do not for all primate clades ( Figure 6A ). We evaluated 348 individual sites within the gene and found that in all primates, a total of 19 residues are 349 under positive selection with a posterior probability > 0.98. One site, position 90, has 350 been implicated in Vif-binding interactions, but only had a posterior probability > 0.98 in 351 one codon model (F3x4; Figure 6A ). Since selection can sometimes be driven by the 352 inclusion of specific clades in the analysis, we also condensed our analysis to Old World 353 monkeys alone and found that 5 sites remain under positive selection (blue arrows, 354 Figure 6B ), all of which are polymorphic in AGMs (Table 1) In order to test the hypothesis that the changes in A3H in the lineages leading to 359 the AGMs were not driven by the Vif protein of the lentiviruses that infect AGMs, we 360 tested the restriction capabilities of the node 1 and node 2 ancestors against HIV-1 361 proviruses expressing SIVagm Vif. We also included the codon-optimized AGM A3H 362 since, as it is isolated from an AGM, should be susceptible to degradation by all Vifs 363 encoded by SIVagm. Of interest, the node 2 ancestor encodes an aspartic acid (D) at 364 amino acid 100, which has previously been important for differences in Vif-biding for 365
SIVcpz and HIV-1, while the node 1 ancestor and all AGM A3Hs encode an asparagine 366 (N) (35, 36) . The antiviral activity of all ancestors, as well as codon-optimized AGM 367 A3H, was counteracted by each Vif, resulting in a rescue of viral infection ( Figure 6C) . 368
Because there are no differences in the ability of Vif to rescue viral infection, these data 369 suggest that Vif is not the primary force on A3H evolution in AGMs, which is instead 370 driven by different selective pressures. 371
Discussion 373
We show evidence for the recurrent functional loss of APOBEC3H in primates. 374
We found that a decrease in protein expression levels, as well as amino acid mutation 375 in the N-terminal region, results in lower antiviral activity. Using molecular reconstruction 376 of ancestral A3H sequences, we found that the most recent common ancestor of AGMs 377 and patas monkeys likely encoded an active A3H, similar to other common ancestors 378 throughout evolutionary history. This suggests that the recurrent loss is a more recent 379 event in primate evolution. Selective pressure by Vif is does not appear to be a primary 380 force behind the evolution of A3H in the AGM clade, but, as loss has occurred both in 381 humans and in other Old world monkeys, there may be a fitness cost to encoding this 382 mutator protein over long evolutionary time periods. 383 384 Molecular evolution of A3H protein impacts expression levels and antiviral 385
activity. 386
While increasing the amount of A3H present in cells did increase its capability to 387 inhibit viral infection, greater antiviral activity does not perfectly correlate with higher 388 protein expression. Surprisingly, codon-optimization increased both the expression level 389 and antiviral activity of A3H. However, codon-optimized AGM A3H haplotype 1 was not 390 as potent as codon-optimized rhesus macaque A3H, demonstrating that both protein 391 expression level and amino acid differences have functional consequences ( Figure 3A  392 and B). In support of this idea, while AGM A3H haplotypes 1 and 8 have the fewest 393 amino acid changes from the most recent common ancestor with another species 394 (Table 2, Figure 5A ). Multiple mutations are required to allow the inactive extant protein 395 to act like its active ancestor. Position 48 is fixed in AGMs, indicating that this change 396 likely occurred first, while subsequent amino acid changes concurrently altered the 397 antiviral activity of the protein. However, a K48Q mutation in the node 1 ancestor does 398 not decrease its function ( Figure 5C ), demonstrating that epistasis between observed 399 amino acid changes more likely lead to its loss. For instance, the AGM A3H double 400 mutant H18R/Q48K inhibits viral infection more comparable to the node 1 ancestor 401 while the individual mutants do not, indicating that both residues are required to gain 402 antiviral activity ( Figure 5B ). Other AGM A3H haplotypes have also accumulated 403 additional nonsynonymous mutations (Figure 2A) , indicating that additional genetic drift 404 may be actively driving A3H to become less antiviral in AGMs, as many animals encode 405 proteins with different expression levels and antiviral activity ( Figure 2B and C) . 406 407 Why has primate A3H maintained partial activity rather than a complete loss? 408
Loss of protein activity can be indicative of a fitness cost. In the case of human 409 A3H, haplotypes encoding unstable proteins have been linked to greater cancer risk, 410 likely due to its nuclear localization and proximity to host DNA (19). Moreover, human 411 A3H haplotypes III and IV, which have a deletion at amino acid 15, have little to no 412 antiviral activity. We observe that AGM A3H haplotypes vary greatly in their antiviral 413 restriction and can restrict viral infection anywhere from 17 -70% (Figure 2A) . 414
However, despite this immense variation in AGM A3H antiviral activity, we observed no 415 large deletions or premature stop codons, which would indicate that the gene itself is 416 being lost. Why has the antiviral activity of A3H not been lost completely in AGMs? It is 417 possible that A3H has been co-opted for a non-antiviral function in Old World monkeys, 418 thus it is preserved. Alternatively, A3H could be retained through linkage to protective 419 A3G haplotypes. A3G and A3H are located close together on chromosome 19 in AGMs, 420 meaning A3H haplotypes that have ultimately lost most of their function may still be 421 passed onto offspring, particularly if the A3G allele encodes a protein providing a 422 selective advantage. In support of this idea, we noticed poorly active A3H proteins in a 423 monkey encoding protective A3G, as characterized in a separate study (8). This 424 individual, V005, encodes A3H haplotype 11 as well as an A3G haplotype that cannot 425 be antagonized by Vif proteins from SIVagm.ver or SIVagm.tan. Since A3G is a more 426 potent antiviral and this protein protects individuals from two strains of SIVagm, the 427 protection it supplies may supersede any detrimental effects incurred by the presence of 428 an inactive A3H haplotype. to an RNA duplex (32-34). We similarly identified that amino acids 18 and 20, found 436 within loop 1, are important for increasing the antiviral activity of AGM A3H (Figure 5B) . 437
The analogous locations of such residues may suggest that these changes impact the 438 antiviral activity of A3H by affecting its capability to bind to viral RNA. Dual amino acid 439 changes at residues 18 and 20 in AGMs increase the antiviral activity of A3H close to 440 the levels of a recent common ancestor. An additional mutation close to the catalytic 441 site, Q48K, together with either H18R or S20N in AGMs, further increased antiviral 442
activity. Furthermore, we found that amino acid 17 similarly increased the antiviral 443 activity of patas monkey A3H. This residue is polymorphic in AGMs, suggesting that this 444 change may have occurred in a common ancestor not tested in this study. We also find 445 that other Old World monkeys have changes within loop 1, such as a six amino acid 446 deletion of residues 18 -23 in De Brazza's monkey and an R18H mutation in talapoin 447
( Figure 5A ). The diversity within loop 1 of Old World monkey A3H is indicative that A3H 448 activity was possibly lost multiple times independently. RNA-binding has been shown to 449 play an important role in the antiviral activity of A3H (32, 33) and thus loss of RNA-450 binding may result in functional loss. 451 452
Vif does not appear to play a role in evolution of A3H along lineage leading to 453
AGMs 454
AGMs are highly polymorphic in a number of antiviral genes that are specific to 455 infection with lentiviruses in both AGMs explicitly and other primates (31), further 456 highlighting the adaptation to SIV within this particular species. Indeed, we found that 457 multiple sites in A3H are under positive selection in primates, which is suggestive of an 458 evolutionary arms race between A3H and another protein. Evidence of A3H-Vif 459 interactions are evident in hominoids, as SIVcpz Vif adaptation to stable human A3H 460 was crucial for transmission of SIVcpz (11) to humans and HIV-1 Vif is highly variable in 461 its ability to target stable human A3H proteins (17, (21) (22) (23) . Interactions between Vif and 462 other A3 proteins have also been well-characterized in chimpanzees and humans (7, 463 35, 36) . Multiple A3s in chimpanzees protect them from infection by SIVs in Old World 464 monkeys. Therefore, Vif must adapt to antagonize multiple A3 proteins such as A3D 465 and A3G (10). However, we find that Vif did not play a role in A3H's evolution in AGMs 466 since ancestral proteins were comparably susceptible to antagonism by Vif. Loss of 467 A3H function may facilitate cross-species transmission of SIVagm strains between AGM 468 subspecies (40) due a diminished A3 repertoire. Although many A3 proteins in the 469 family may be redundant, encoding a diverse range of A3s is likely important to achieve 470 maximum protection against lentiviruses. 471
Since lentiviruses have infected simian primates for millions of years (7), it is 472 unlikely that the lack of residues altering A3H-Vif interactions in AGMs stems from 473 recent infection of Old World monkeys. It is possible that the changes are the result of 474 genetic drift or driven by a different viral pathogen in these primates. Conversely, 475 positively selected residues may indicate evolutionary toggling to preserve or eliminate 476 protein function. This is supported by the finding that many amino acid residues found to 477 increase the antiviral activity of A3H in AGMs are under positive selection ( Figure 6A , 478 6B). It is also possible that the relative importance of different A3 proteins may change 479 dependent on the evolutionary history of a species, driven by the redundancy of the 480 protein family. In the Old World monkeys studied here, inactive A3H proteins may 481 impart an increased risk for host genome mutations, thus its function was lost due to the 482 balance between viral protection and host fitness. 483
484
Our data implies that A3H function was lost prior to the divergence of different 485
SIVagm strains due to its inactivity in all AGMs, not just specific subspecies. If this is the 486 case, Vif proteins from the ancestral virus may not have required adaptation to escape 487 the antiviral activity of A3H and instead evolved in response to pressure from the more 488 potent A3G. Expansion of the primate A3 locus provides flexibility of this antiviral protein 489 family to take different trajectories throughout evolution. We have demonstrated that 490 A3H activity is fluid throughout the evolutionary history of primates. In addition to 491 previous work in humans, the A3H homolog in felines, APOBEC3Z3, was recently 492
shown have a similar functional loss (41), demonstrating that loss of A3H and its 493 homologs are frequent throughout a variety of animal species. Such widespread loss of 494 function is suggestive of a potential fitness cost to hosts, although the presence of 495 modern and active A3H proteins exemplifies the importance of encoding a diverse A3 496 locus in primates. 497
Materials and methods 498
APOBEC3H cDNA Amplification and Sequencing. 499 Primate A3H genes were cloned from cDNA. A 5' hemagluttinin (HA) tag was added via 520
PCR (Forward: 521
GTGGTGGAATTCATGTATCCATACGATGTTCCAGATTACGCTGCTCTGCT Reverse: 522 CTAGACTCGAGTCATCTTGAGTT). The products were digested using EcoRI/XhoI 523 restriction enzymes and ligated into a mammalian pcDNA 3.1 vector (Invitrogen, 524 #V79020). Site-directed mutagenesis was completed with the QuikChange II Site-525
Directed Mutagenesis Kit (Agilent, #200524) to construct all ancestral genes and 526 mutants. The A3H gene from patas monkeys was generated by gene synthesis (IDT) 527 and cloned into the pcDNA 3.1 backbone. A3H genes from AGM and rhesus macaque 528 were codon-optimized based on usage frequencies in primates (human and rhesus 529 macaque) to remove rare codons within the gene in Geneious (Biomatters Ltd.). Codon-530 optimized sequences were generated by gene synthesis and cloned into pcDNA 3.1. 531 532 Cell Lines, Transfections, and Western Blot Analysis. 533 HEK293T, HeLa, and Cos7 cell lines (ATCC) were maintained in Dulbecco's modified 534
Eagle's medium (DMEM) with 10% fetal bovine serum (Corning, #35-015-CV) and 100 535 g/mL penicillin/streptomycin (Gibco, #15140-122) at 37C. SupT1 cells (ATCC) were 536 maintained in RPMI 1640 with 10% fetal bovine serum and 100 g/mL 537 penicillin/streptomycin in the same conditions. Transfections were done in serum-free 538 DMEM with TransIT-LT1 transfection reagent (Mirus Bio, #MIR 2305) at a 539 reagent:plasmid DNA ratio of 3:1. For western blot analysis, cells were lysed in ice-cold 540 NP40 buffer (0.5% NP40, 20mM NaCl, 50mM Tris pH 7.5) with protease inhibitors 541 (Roche Complete Mini, EDTA-free tablets, #11836170001). Lysates were quantified 542 using a Pierce BCA Protein Assay Kit (Thermo Scientific, #23225) and 10 g of protein 543 was resolved by SDS-PAGE, transferred to a PVDF membrane, and probed with anti-544 HA (BioLegend, #901503) and anti-actin (Sigma, #A2066) or anti-vinculin (Proteintech, 545 #66305-1) antibodies at a 1:2000 dilution. Anti-mouse or anti-rabbit secondary 546 antibodies were used at a 1:5000 dilution (Santa Cruz Biotechnology, sc-2005 , sc-547 2004 . 548 549
Immunofluorescence. 550
HeLa cells were seeded onto 18mm (VWR, #48380 046) coverslips seeded with 4 x 10 4 551 cells/mL and transfected with 500 ng of A3H-expressing plasmids the next day. 48 552 hours after transfection, the coverslips were fixed in 2% paraformaldehyde, 553 permeabilized in 0.5% PBS/Triton-X, and blocked in PBS/BGS. HA-tagged proteins 554 were detected using the same HA antibody used for western blots at a 1:1000 dilution 555 followed by an anti-mouse AF488 antibody at 1:400 (Invitrogen, #A11001). Nuclei were 556 stained in SlowFade Gold antifade reagent with DAPI mounting media (Life 557
Technologies, #S36939). Images were taken on a Nikon E800 microscope. The 27 primate A3H sequence alignment was analyzed using HyPhy GARD analysis to 569 ensure there was no recombination in the gene (42). The species phylogeny (27) was 570 input into the CODEML sites model of PAML (39) along with the nucleotide alignment to 571 detect positive selection at individual sites. The p-value was calculated by twice the 572 difference in log-likelihood between models M7 and M7 as well as M8 and M8a with two 573 degrees of freedom. Analysis was conducted with both the F3x4 and F61 codon 574 frequency models with omega values of 0.4 and 1.5. Data from F3x4 and F61 models 575 are shown in Table 1 . Positively selected sites were categorized as those with an M8 576
Bayes Empirical Bayes posterior probability greater than 98%. 577 578 Ancestral Reconstruction. 579
The ancestors at specific nodes within the Old World monkey clade were reconstructed 580 using the FASTML webserver (fastml.tau.ac.il; last accessed March 2018; (37)). The 27 581 primate A3H sequence alignment was used in conjunction with the species tree to 582 generate marginal reconstructions of codon sequences. 583 584
Single-Cycle Infectivity Assays. 585
HEK293T cells were plated in 1mL in 12-well plates at 1.25 x 10 5 cells/mL. After cells 586 reached between 50 -70% confluency, they were co-transfected with 250 ng of A3H or 587 empty expression plasmid, 600 ng of proviral plasmid, and 100 ng of L-VSV-G 588 (vesicular stomatitis virus glycoprotein) for pseudotyping in 100 L serum-free medium 589
with TransIT-LT1 transfection reagent (Mirus Bio). Supernatants containing virus were 590 harvested after 48 hours and clarified through 0.2-micron filters. Viral titers were 591 determined by measuring reverse-transcriptase (RT) activity by qPCR as described 592 previously (43). In short, viral supernatants were lysed in 2X lysis buffer (0.25% Triton 593 were detected with an anti-HA antibody (green) and DAPI staining was used to detect 788 the nucleus (blue). Image is representative of n = 90 total images over 3 replicates. 789 Numbered amino acid residues that are different between AGM A3H, patas A3H, and 806 the node 1 ancestor are outlined in red on the protein sequence alignment, ancestral 807 residues are colored blue. B. Top: Single-cycle infectivity assay for HIVvif against 808 extant mutants. Relative infection was normalized to viral infectivity in the absence of A3 809 proteins. Averages of two replicates, each with triplicate infections (  SEM) are shown. 810
Figure Legends
Bottom: Western blot analysis of protein expression levels of HA-tagged extant mutants 811 made in the AGM and patas A3H backgrounds. Vinculin is used as a loading control. C. 812
Top: Single-cycle infectivity assay for HIVvif against AGM haplotype 1, node 1 813 ancestor, and node 1 mutant A3H. Relative infection was normalized to viral infectivity 814 in the absence of A3 proteins. Averages of two replicates, each with triplicate infections 815 (  SEM) are shown. Dotted line at 10% is an arbitrary reference point. Bottom: Western 816 blot analysis of protein expression levels of HA-tagged proteins made in the AGM and 817 patas A3H backgrounds. Vinculin is used as a loading control. D. A partial species 818 phylogeny, shown as a cladogram, accompanied by amino acid residues across Old 819
World monkeys at sites found to be important for antiviral activity. 820 
Amino acid position with nonsynonymous mutations across the tested haplotypes. Boxes colored in red have a different amino acid residue relative to AGM A3H haplotype 1.
